Bronchiolitis Obliterans Clinical Trials
Here are the 2 most popular medical studies for bronchiolitis obliterans
Janus Kinase (JAK) Inhibitor
Continued Itacitinib Treatment for Myelofibrosis
This trial is designed to provide itacitinib to people who have already been taking it and who may benefit from continued treatment. Eligible participants will receive the same dose and schedule of itacitinib as they received in the previous study. Treatment may be continued as long as the participant does not experience negative side effects, still derives benefit from the drug, and does not meet any other criteria for discontinuation.
Popular filter options for bronchiolitis obliterans trials
Bronchiolitis Obliterans Syndrome Clinical Trials
View 7 Bronchiolitis Obliterans Syndrome medical studies.
Immunomodulator
ARINA-1 for Bronchiolitis Obliterans Syndrome
This trial compares the effectiveness of a new drug to the existing standard of care for lung transplant recipients to see if it can improve quality of life and prevent or delay the need for additional treatment.
Janus Kinase Inhibitor
Ruxolitinib for Lung Dysfunction Post Stem Cell Transplant
This trial is testing whether a new combination of drugs can help treat a common and serious side effect of a stem cell transplant that often leads to long-term problems or even death.
Immunosuppressant
L-CsA + Standard of Care for Bronchiolitis Obliterans Syndrome
This trial is testing how safe and effective L-CsA plus Standard of Care is in treating Breathing Obstruction Syndrome in people who have had either a single or double lung transplant.
Neutrophil Elastase Inhibitor
Alvelestat for Bronchiolitis Obliterans Syndrome
This trial is testing a new drug, alvelestat (MPH966), to see if it's safe and effective in treating bronchiolitis obliterans syndrome (BOS). BOS is a complication people can experience after hematopoietic stem cell transplant.
Immunosuppressant
LAM-001 for Bronchiolitis Obliterans Syndrome
This trial will investigate the safety and effectiveness of inhaled sirolimus to slow bronchiolitis obliterans syndrome (BOS) progression in lung transplant recipients. Participants will be randomly assigned to inhale sirolimus or placebo for 48 weeks and attend 10 visits.
BOS Clinical Trials
View 7 BOS medical studies.
Immunomodulator
ARINA-1 for Bronchiolitis Obliterans Syndrome
This trial compares the effectiveness of a new drug to the existing standard of care for lung transplant recipients to see if it can improve quality of life and prevent or delay the need for additional treatment.
Janus Kinase Inhibitor
Ruxolitinib for Lung Dysfunction Post Stem Cell Transplant
This trial is testing whether a new combination of drugs can help treat a common and serious side effect of a stem cell transplant that often leads to long-term problems or even death.
Immunosuppressant
L-CsA + Standard of Care for Bronchiolitis Obliterans Syndrome
This trial is testing how safe and effective L-CsA plus Standard of Care is in treating Breathing Obstruction Syndrome in people who have had either a single or double lung transplant.
Neutrophil Elastase Inhibitor
Alvelestat for Bronchiolitis Obliterans Syndrome
This trial is testing a new drug, alvelestat (MPH966), to see if it's safe and effective in treating bronchiolitis obliterans syndrome (BOS). BOS is a complication people can experience after hematopoietic stem cell transplant.
Immunosuppressant
LAM-001 for Bronchiolitis Obliterans Syndrome
This trial will investigate the safety and effectiveness of inhaled sirolimus to slow bronchiolitis obliterans syndrome (BOS) progression in lung transplant recipients. Participants will be randomly assigned to inhale sirolimus or placebo for 48 weeks and attend 10 visits.
Bronchiolitis Obliterans Clinical Trials With No Placebo
View 13 bronchiolitis obliterans medical studies that do not have a placebo group.
Immunomodulator
ARINA-1 for Bronchiolitis Obliterans Syndrome
This trial compares the effectiveness of a new drug to the existing standard of care for lung transplant recipients to see if it can improve quality of life and prevent or delay the need for additional treatment.
Janus Kinase Inhibitor
Ruxolitinib for Lung Dysfunction Post Stem Cell Transplant
This trial is testing whether a new combination of drugs can help treat a common and serious side effect of a stem cell transplant that often leads to long-term problems or even death.
Immunosuppressant
L-CsA + Standard of Care for Bronchiolitis Obliterans Syndrome
This trial is testing how safe and effective L-CsA plus Standard of Care is in treating Breathing Obstruction Syndrome in people who have had either a single or double lung transplant.
Frequently Asked Questions
Introduction to bronchiolitis obliterans
What are the top hospitals conducting bronchiolitis obliterans research?
Bronchiolitis obliterans, a rare and serious lung condition, is being met head-on by top hospitals across the United States. In Cleveland, the renowned Cleveland Clinic takes the lead with their dedicated efforts in this field. With six ongoing clinical trials focused on bronchiolitis obliterans and eight completed studies to date, they have been at the forefront of research since 2008 when they first recorded a trial for this condition. Meanwhile, Houston Methodist Hospital in Texas has also made significant contributions with four active trials and a total of four completed studies since their initial investigation began in 2019.
In Dallas, Baylor University Medical Center joins the ranks with its focus on bronchiolitis obliterans. They currently have four active trials underway along with an equal number of completed studies. Their journey into understanding this complex disease started in 2015 when they recorded their first trial. Further south in Tampa, Florida's University of South Florida is making strides as well. With three ongoing trials and three prior investigations under their belt since recording their inaugural bronchiolitis obliterans study in 2019.
Lastly,Banner Health located in Phoenix is playing an essential role through its involvement in tackling bronchiolitis obliterans as well; although appearing smaller-scale compared to others listed here but nevertheless equally significant.They are actively participatingin three clinical trials pertaining to this condition while having conductedthree previous investigations ever since marking its foundation within same year of commencement way back till recent times.The dedication demonstrated by these hospitals signifies not only their commitment to advancing treatment options for those affected by bronchiolitis obliterans but also highlights how collaboration across different locations can contribute towards improving patients' lives nationwide
Which are the best cities for bronchiolitis obliterans clinical trials?
When it comes to bronchiolitis obliterans clinical trials, several cities are at the forefront of research and development. Philadelphia leads the way with 10 active trials, exploring treatments such as itacitinib and liposomal cyclosporine A. Boston, Baltimore, Dallas, and Columbus also contribute significantly to this field with their ongoing studies on various interventions for bronchiolitis obliterans. These cities provide individuals affected by this condition access to cutting-edge clinical trials that may lead to improved treatment options and better outcomes.
Which are the top treatments for bronchiolitis obliterans being explored in clinical trials?
Bronchiolitis obliterans, a challenging respiratory condition, is the focus of ongoing clinical trials exploring potential treatments. Noteworthy among these investigations are itacitinib and liposomal cyclosporine A, both showing promise with two active trials each dedicated to bronchiolitis obliterans. Itacitinib burst onto the scene in 2020 and has since become a subject of interest with its fresh approach. Liposomal cyclosporine A made its mark in 2019 and continues to be explored for its therapeutic potential. Additionally, sirolimus has caught researchers' attention as an emerging treatment option, currently being studied in one active trial for bronchiolitis obliterans since its listing in 2023. As medical experts continue their unwavering quest for solutions, these innovative therapies offer hope on the horizon for individuals affected by this debilitating lung disease.
What are the most recent clinical trials for bronchiolitis obliterans?
Bronchiolitis obliterans, a debilitating lung condition, has seen recent advancements through clinical trials that offer hope and potential treatment options. Sirolimus showcased promising results in Phase 2 trials as a potential therapeutic approach for bronchiolitis obliterans patients. Another trial, ARINA-1, combined with standard of care treatments exhibited promise in Phase 3 studies to improve outcomes for individuals with this condition. Ruxolitinib and itacitinib have also undergone Phase 2 and 1 trials respectively, providing further avenues for exploration in the quest to combat bronchiolitis obliterans. These recent clinical trials mark crucial steps forward towards enhancing the management and treatment of this challenging respiratory disease.
What bronchiolitis obliterans clinical trials were recently completed?
Stanford University recently completed a clinical trial investigating the efficacy of Pirfenidone 267 MG [Esbriet] for bronchiolitis obliterans in March 2018. This study represents an important step in advancing our understanding and potential treatments for this challenging respiratory disease.